Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer
About this item
Full title
Author / Creator
Publisher
United States: UBM LLC
Journal title
Language
English
Formats
Publication information
Publisher
United States: UBM LLC
Subjects
More information
Scope and Contents
Contents
Skeletal-related events contribute substantially to morbidity, mortality and cost in men with metastatic castration-resistant prostate cancer (mCRPC). There are five agents available for treatment in mCRPC that reduce skeletal-related events. Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radiu...
Alternative Titles
Full title
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1690649291
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1690649291
Other Identifiers
ISSN
0890-9091
